Medical Device – Page 6

FDA Grants Emergency Authorization for Invivyd’s Pemgarda Antibody Prophylactic Against COVID-19 in Immunocompromised Individuals

1 year ago talkbio0Tagged Adolescent (age group), Adults/, Approved, Condoms, Male, COVID19 (disease), Emergency Use Authorization, Half-Life Extended Monoclonal Antibody, immune compromise, Immunocompromised Host, Invivyd, Moderate (severity modifier), Pemgarda, pemivibart, Pre-Exposure Prophylaxis, Prophylactic treatment, Severe (severity modifier), United States Food and Drug Administration, VYD222

Invivyd, Pemgarda (pemivibart; formerly VYD222), Half-Life Extended Monoclonal Antibody, COVID-19 Prophylactic, Immunocompromised Patients, Emergency Use Authorization (EUA), FDA Approval, Moderate to Severe Immune Compromise, Pre-exposure Prophylaxis (Prevention) of COVID-19 in Adults/ Adolescents

AstraZeneca Joins Price Cap Movement for Inhalers Following Boehringer Investigation

1 year ago talkbio0Tagged AstraZeneca, Evaluation, Inhaler, Prices, SmithKline Beecham

Evaluation, Inhaler, AstraZeneca, SmithKline Beecham, Prices

Boehringer Ingelheim Caps Out-of-Pocket Costs for Asthma and COPD Inhalers in the U.S.

1 year ago talkbio0Tagged Asthma, boehringer ingelheim, Caps, Chronic Obstructive Airway Disease, Inhaler, June 1, 2024, List price reduction, Out of Pocket Payment, under-insured, Uninsured

Boehringer Ingelheim, Out-of-pocket costs, Asthma, COPD, Inhalers, $35 cap, June 1/ 2024, Uninsured and under-insured patients, List price reduction